Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shingo Dan

Showing results (61-70 of 83) with videos related to

Pageof 9
Sort By:
Oncotarget|November 13, 2018
Antitumor profile of the PI3K inhibitor ZSTK474 in human sarcoma cell linesNachi Namatame, Naomi Tamaki, Yuya Yoshizawa, et al.
Cancer Research Communications|March 31, 2026
Cooperative roles of class IA PI3K isoforms in translocation-related sarcoma cell survival and proliferationSho Isoyama, Naomi Tamaki, Yutaka Noguchi, et al.
Science Signaling|November 12, 2024
Metabolically inducing defects in DNA repair sensitizes <i>BRCA</i>-wild-type cancer cells to replication stressKenji Watanabe, Tatsuro Yamamoto, Tomoko Fujita, et al.
ACS Chemical Biology|November 3, 2021
Identification of Dihydroorotate Dehydrogenase Inhibitors─Indoluidins─That Inhibit Cancer Cell GrowthMakoto Kawatani, Harumi Aono, Takeshi Shimizu, et al.
Oncotarget|February 9, 2018
Targeting the Golgi apparatus to overcome acquired resistance of non-small cell lung cancer cells to EGFR tyrosine kinase inhibitorsYoshimi Ohashi, Mutsumi Okamura, Ryohei Katayama, et al.
Cancer Science|April 28, 2015
Comprehensive transcriptomic analysis of molecularly targeted drugs in cancer for target pathway evaluationTetsuo Mashima, Masaru Ushijima, Masaaki Matsuura, et al.
Oncology Research|September 25, 2023
Identification of a dihydroorotate dehydrogenase inhibitor that inhibits cancer cell growth by proteomic profilingMakoto Kawatani, Harumi Aono, Sayoko Hiranuma, et al.
Bioorganic & Medicinal Chemistry|August 29, 2015
Ridaifen G, tamoxifen analog, is a potent anticancer drug working through a combinatorial association with multiple cellular factorsKentaro Ikeda, Shinji Kamisuki, Shoko Uetake, et al.
Bioorganic & Medicinal Chemistry|December 20, 2020
(S)-Erypoegin K, an isoflavone isolated from Erythrina poeppigiana, is a novel inhibitor of topoisomerase IIα: Induction of G2 phase arrest in human gastric cancer cellsKiyomi Hikita, Yuko Yamakage, Honoka Okunaga, et al.
Cancer Science|July 15, 2024
Cytochrome P450 2J2 is required for the natural compound austocystin D to elicit cancer cell toxicityYukiko Kojima, Saki Fujieda, Liya Zhou, et al.
Pageof 9

Showing results (61-70 of 83) with videos related to

Sort By:
Pageof 9
Oncotarget|November 13, 2018
Antitumor profile of the PI3K inhibitor ZSTK474 in human sarcoma cell linesNachi Namatame, Naomi Tamaki, Yuya Yoshizawa, et al.
Cancer Research Communications|March 31, 2026
Cooperative roles of class IA PI3K isoforms in translocation-related sarcoma cell survival and proliferationSho Isoyama, Naomi Tamaki, Yutaka Noguchi, et al.
Science Signaling|November 12, 2024
Metabolically inducing defects in DNA repair sensitizes <i>BRCA</i>-wild-type cancer cells to replication stressKenji Watanabe, Tatsuro Yamamoto, Tomoko Fujita, et al.
ACS Chemical Biology|November 3, 2021
Identification of Dihydroorotate Dehydrogenase Inhibitors─Indoluidins─That Inhibit Cancer Cell GrowthMakoto Kawatani, Harumi Aono, Takeshi Shimizu, et al.
Oncotarget|February 9, 2018
Targeting the Golgi apparatus to overcome acquired resistance of non-small cell lung cancer cells to EGFR tyrosine kinase inhibitorsYoshimi Ohashi, Mutsumi Okamura, Ryohei Katayama, et al.
Cancer Science|April 28, 2015
Comprehensive transcriptomic analysis of molecularly targeted drugs in cancer for target pathway evaluationTetsuo Mashima, Masaru Ushijima, Masaaki Matsuura, et al.
Oncology Research|September 25, 2023
Identification of a dihydroorotate dehydrogenase inhibitor that inhibits cancer cell growth by proteomic profilingMakoto Kawatani, Harumi Aono, Sayoko Hiranuma, et al.
Bioorganic & Medicinal Chemistry|August 29, 2015
Ridaifen G, tamoxifen analog, is a potent anticancer drug working through a combinatorial association with multiple cellular factorsKentaro Ikeda, Shinji Kamisuki, Shoko Uetake, et al.
Bioorganic & Medicinal Chemistry|December 20, 2020
(S)-Erypoegin K, an isoflavone isolated from Erythrina poeppigiana, is a novel inhibitor of topoisomerase IIα: Induction of G2 phase arrest in human gastric cancer cellsKiyomi Hikita, Yuko Yamakage, Honoka Okunaga, et al.
Cancer Science|July 15, 2024
Cytochrome P450 2J2 is required for the natural compound austocystin D to elicit cancer cell toxicityYukiko Kojima, Saki Fujieda, Liya Zhou, et al.
Pageof 9